CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 37 enrolled
Drug / intervention
RT-CGMdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01474889
NCT01474889N/ACompleted
CompareCT.gov

Effect of Real-Time Continuous Glucose Monitoring on Glucose Counterregulation in Long Standing Type 1 Diabetes

University of Pennsylvania·interventional·Posted Nov 18, 2011·Updated Aug 31, 2023

In Brief

A clinical study evaluating RT-CGM for Hypoglycemia Unawareness and 2 related conditions. Completed, enrolled 37 participants across 3 sites.

Detailed Summary

Enrollment for this study is complete. This study is designed to determine if use of a real-time continuous glucose monitor (RT-CGM) can reverse defective Glucose counter regulation and hypoglycemia unawareness in long standing type 1 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoglycemia Unawareness, Type 1 Diabetes, Healthy
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 18, 2011
Enrollment StartOct 1, 2011
Primary CompletionMay 1, 2016
Study CompletionMar 5, 2021
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 14.6 years ago

Interventions

RT-CGMdevice

Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.